Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
RBM5
REST API REST API
Homo sapiens
RBM5 is differentially expressed in 333 experiments: 152 organism parts: liver, lung, ... (150 more);, 230 disease states: normal, acute myeloid leukemia, ... (228 more);, 106 cell types 442 cell lines 45 compound treatments and 93 other conditions.
Synonyms LUCA15, H37
Orthologs RBM5_BOVIN (Bos taurus)   ENSCING00000002585 (Ciona intestinalis)   RBM5 (Gallus gallus)   Rbm5 (Rattus norvegicus)   Rbm5 (Mus musculus)   rbm5 (Danio rerio)   CG4887 (Drosophila melanogaster)   RBM5 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term RNA splicing, DNA binding, protein binding, RNA processing, intracellular, regulation of alternative nuclear mRNA splicing, via spliceosome, negative regulation of cell proliferation, metal ion binding, nucleic acid binding, positive regulation of apoptosis, spliceosomal complex, mRNA binding, nucleus, nucleotide binding, nuclear mRNA splicing, via spliceosome, nucleoplasm, spliceosome assembly, RNA binding, zinc ion binding, gene expression
InterPro Term Znf_RanBP2, Znf_C2H2, G_patch, RRM_dom
UniProt Accession C9J9P7, P52756, C9JFQ5, C9JR02, Q59HE6, E1CJT4, F5H384, F8WE23, F8W910
Search EB-eye ENSG00000003756
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-22541, E-GEOD-6573, E-GEOD-1577, E-GEOD-3526, ... (29 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (41 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-3529, E-GEOD-20081, E-GEOD-5823
T84
2
E-GEOD-1474, E-MTAB-37
AGS
2
E-MTAB-37, E-GEOD-15460
BT20
2
E-MTAB-37, E-MTAB-62
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
MOLT4
2
E-MTAB-62, E-MTAB-37
436 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-2822, E-GEOD-21909, ... (49 experiments)

Factor Value U/D Experiments
1
2
E-TABM-145, E-TABM-130
fibroblast
2
E-GEOD-3920, E-GEOD-26672
CD8+ T cell
1
2
E-AFMX-5, E-TABM-145, E-GEOD-6740
T cell
1
2
E-GEOD-13987, E-GEOD-6053, E-GEOD-16190
leydig cell
1
E-MTAB-25
LCC
1
E-GEOD-19188
100 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, E-GEOD-1577, ... (67 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
3
E-MTAB-37, E-MTAB-62, E-GEOD-2514
extranodal NK/T-cell lymphoma
2
E-TABM-702, E-GEOD-19067
acute promyelocytic leukemia
2
E-MTAB-62, E-GEOD-995
acute quadriplegic myopathy
2
E-MTAB-62, E-GEOD-3307
adenocarcinoma
2
E-MTAB-62, E-MTAB-37
colon carcinoma
2
E-MTAB-37, E-GEOD-3726
224 more value(s).


Compound treatment

studied in E-GEOD-5258, E-TABM-782, E-GEOD-697, E-GEOD-5824, E-TABM-868, ... (29 experiments)

Factor Value U/D Experiments
none
2
11
E-GEOD-697, E-GEOD-5824, E-TABM-868, E-GEOD-5099, E-GEOD-412, ... (13 experiments)
hydroxyurea
1
E-GEOD-6431
control - IL-1b
1
E-GEOD-7216
vitamin E
1
E-MEXP-1327
NaOH
1
1
E-MEXP-2590
epidermal growth factor
1
E-GEOD-6462
39 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519


Biosource provider
studied in E-TABM-325, E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (12 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-21374, E-GEOD-2034, ... (9 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-1614, E-MEXP-2359, E-GEOD-2666, E-GEOD-4667, E-GEOD-3891, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-7788, E-GEOD-3325, E-TABM-26, E-GEOD-22148, ... (9 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, ... (7 experiments)

Genotype
studied in E-GEOD-17476, E-GEOD-2466, E-GEOD-22593, E-GEOD-18005, E-TABM-868, ... (14 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, E-GEOD-10315, E-GEOD-837, ... (13 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-GEOD-1926, E-GEOD-3720, ... (43 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-MEXP-561, E-GEOD-17400, E-GEOD-6802 ... (5 experiments)

Initial distant metastases
studied in E-GEOD-22541

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-GEOD-2004, E-LGCL-5

Phenotype
studied in E-GEOD-19703, E-GEOD-1309, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, ... (8 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, ... (8 experiments)

Replicate
studied in E-GEOD-10797, E-GEOD-19330, E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-MEXP-70, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-19743, E-GEOD-2466, E-GEOD-22541, E-GEOD-7307, E-GEOD-16363 ... (5 experiments)

Stimulation
studied in E-GEOD-13909, E-GEOD-20114, E-GEOD-11428

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276, E-GEOD-2748

Tissue
studied in E-GEOD-30573

tissue (organ)
studied in E-GEOD-22601

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-33562, E-GEOD-16837, E-GEOD-19246, E-GEOD-13818, E-GEOD-19815, ... (7 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-3494, E-GEOD-22541, E-TABM-43, E-GEOD-1561, E-GEOD-4922 ... (5 experiments)

Processing time: 0.382 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM